Keymed Biosciences Inc. (HKG:2162)
60.55
+2.90 (5.03%)
At close: Mar 27, 2026
Keymed Biosciences Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 503.35 | 418.41 | 851.03 | 604.07 | 1,521 |
Short-Term Investments | 1,100 | 1,737 | 1,694 | 2,339 | 1,951 |
Trading Asset Securities | 319.94 | 0.24 | 174.37 | 232.19 | 53.4 |
Cash & Short-Term Investments | 1,924 | 2,156 | 2,719 | 3,175 | 3,525 |
Cash Growth | -10.76% | -20.73% | -14.37% | -9.91% | 895.41% |
Accounts Receivable | 100.85 | 63.73 | 27.97 | 0.48 | 10.55 |
Other Receivables | - | 51.02 | 18.5 | 34.01 | 0.72 |
Receivables | 100.85 | 114.75 | 46.47 | 34.49 | 11.27 |
Inventory | 195.98 | 123.97 | 61.1 | 51.33 | 22.43 |
Restricted Cash | 39.59 | - | 1.78 | - | - |
Other Current Assets | 162.68 | 71.7 | 111 | 48.83 | 23.67 |
Total Current Assets | 2,423 | 2,466 | 2,940 | 3,310 | 3,582 |
Property, Plant & Equipment | 1,299 | 1,048 | 893.74 | 584.43 | 177.53 |
Long-Term Investments | 420.14 | 210.03 | 21.63 | 20.57 | 20.28 |
Other Intangible Assets | 8.07 | 9.75 | 1.11 | 1.5 | 1.1 |
Other Long-Term Assets | 67.17 | 32.66 | 26.91 | 15.84 | 153.59 |
Total Assets | 4,218 | 3,767 | 3,883 | 3,932 | 3,934 |
Accounts Payable | 28.06 | 26.01 | 29.49 | 14.91 | 2.78 |
Accrued Expenses | - | 118.39 | 113.2 | 90.99 | 49.93 |
Short-Term Debt | - | 337.18 | 13.01 | 60.79 | 0.55 |
Current Portion of Long-Term Debt | 509.37 | 135.19 | 32.81 | 0.6 | - |
Current Portion of Leases | 9.52 | 12.36 | 19.43 | 11.08 | 11.72 |
Current Income Taxes Payable | 2.73 | 4.97 | 1.82 | 1.03 | 0.94 |
Current Unearned Revenue | 0.45 | 1.58 | - | - | 1.61 |
Other Current Liabilities | 286.17 | 112.05 | 104.42 | 200.3 | 44.54 |
Total Current Liabilities | 836.29 | 747.73 | 314.18 | 379.7 | 112.08 |
Long-Term Debt | 258.03 | 257.19 | 331.83 | 28.8 | - |
Long-Term Leases | 11.62 | 11.32 | 21.62 | 20.93 | 26.99 |
Long-Term Unearned Revenue | 336.67 | 274.78 | 228.19 | 163.67 | 8.72 |
Long-Term Deferred Tax Liabilities | - | 0.35 | 0.28 | - | - |
Other Long-Term Liabilities | - | - | - | - | 141.29 |
Total Liabilities | 1,443 | 1,291 | 896.11 | 593.1 | 289.07 |
Common Stock | 0.2 | 0.17 | 0.17 | 0.17 | 0.17 |
Additional Paid-In Capital | - | 8,496 | 8,484 | 8,485 | 8,516 |
Retained Earnings | - | -6,165 | -5,649 | -5,290 | -4,982 |
Treasury Stock | -0 | -0 | - | - | - |
Comprehensive Income & Other | 2,774 | 143.07 | 151.76 | 144.97 | 116.82 |
Total Common Equity | 2,774 | 2,475 | 2,986 | 3,340 | 3,651 |
Minority Interest | 0.67 | 0.64 | 0.5 | -1.07 | -5.59 |
Shareholders' Equity | 2,775 | 2,475 | 2,987 | 3,339 | 3,645 |
Total Liabilities & Equity | 4,218 | 3,767 | 3,883 | 3,932 | 3,934 |
Total Debt | 788.54 | 753.24 | 418.71 | 122.19 | 39.26 |
Net Cash (Debt) | 1,135 | 1,402 | 2,300 | 3,053 | 3,485 |
Net Cash Growth | -19.05% | -39.04% | -24.65% | -12.40% | - |
Net Cash Per Share | 4.15 | 5.35 | 8.80 | 11.69 | 21.67 |
Filing Date Shares Outstanding | 282.95 | 275.6 | 276.6 | 277.39 | 279.74 |
Total Common Shares Outstanding | 282.95 | 275.6 | 276.6 | 277.39 | 279.74 |
Working Capital | 1,587 | 1,718 | 2,625 | 2,930 | 3,470 |
Book Value Per Share | 9.80 | 8.98 | 10.80 | 12.04 | 13.05 |
Tangible Book Value | 2,766 | 2,465 | 2,985 | 3,339 | 3,650 |
Tangible Book Value Per Share | 9.78 | 8.94 | 10.79 | 12.04 | 13.05 |
Buildings | - | 190.16 | 190.16 | - | - |
Machinery | - | 692.07 | 626.77 | 235.49 | 110.64 |
Construction In Progress | - | 213.93 | 34.48 | 323.55 | 21.63 |
Leasehold Improvements | - | 62.05 | 60.77 | 51.73 | 42.45 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.